Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

CoVIg3. Development of a rapid diagnostic immunization kit against Coronavirus (SARS-CoV-2) in patients diagnosed or suspected of COVID-19

The CoVIg3 project aims to the development of a portable rapid test (point of care) based on lateral flow technology for the qualitative detection of antibodies generated by the humoral response in patients exposed to contact with coronavirus (SARS-Cov-2), whether they are asymptomatic or with different degrees of the disease. The test will simultaneously multiplex IgA, IgM and IgG Immunoglobulins independently in a single device. The test will have a high sensitivity and specificity, a fast response time (15 min) and low cost.

Moreover, it is intended to analyze the genetic profiles of the Human Leukocyte Antigen (HLA), involved in the response to infections, in order to find haplotypes of sensitivity / resistance to infection, as well as possible predictors of the evolution of the disease in its different degrees.

Finally, the project aims to study the immunization process of patients with suspected or diagnosed COVID-19 by analyzing the humoral response of IgA, IgM and IgG immunoglobulins, in a highly exposed population of enormous strategic value in the fight against the pandemic: health workers.

Collaboration between the Vithas Group and Atrys Health.

Financed by CDTI and co-financed with FEDER funds

2020-2021